176 related articles for article (PubMed ID: 16842141)
1. Hyperhomocysteinemia in movement disorders: Current evidence and hypotheses.
Zoccolella S; Martino D; Defazio G; Lamberti P; Livrea P
Curr Vasc Pharmacol; 2006 Jul; 4(3):237-43. PubMed ID: 16842141
[TBL] [Abstract][Full Text] [Related]
2. Genetic and environmental factors for hyperhomocysteinaemia and its clinical implications in Parkinson's disease.
Białecka M; Robowski P; Honczarenko K; Roszmann A; Sławek J
Neurol Neurochir Pol; 2009; 43(3):272-85. PubMed ID: 19618311
[TBL] [Abstract][Full Text] [Related]
3. Hyperhomocysteinemia in L-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.
Lamberti P; Zoccolella S; Armenise E; Lamberti SV; Fraddosio A; de Mari M; Iliceto G; Livrea P
Eur J Neurol; 2005 May; 12(5):365-8. PubMed ID: 15804266
[TBL] [Abstract][Full Text] [Related]
4. Homocysteine and Hyperhomocysteinaemia.
Zaric BL; Obradovic M; Bajic V; Haidara MA; Jovanovic M; Isenovic ER
Curr Med Chem; 2019; 26(16):2948-2961. PubMed ID: 29532755
[TBL] [Abstract][Full Text] [Related]
5. [Homocysteine and its role in pathogenesis of Parkinson's disease and other neurodegenerative disorders].
Szadejko K; Szabat K; Ludwichowska A; Sławek J
Przegl Lek; 2013; 70(7):443-7. PubMed ID: 24167945
[TBL] [Abstract][Full Text] [Related]
6. Homocysteine Levels in Parkinson's Disease: Is Entacapone Effective?
Kocer B; Guven H; Comoglu SS
Biomed Res Int; 2016; 2016():7563705. PubMed ID: 27493964
[TBL] [Abstract][Full Text] [Related]
7. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
[TBL] [Abstract][Full Text] [Related]
8. Plasma homocysteine level and its relationship to clinical profile in Parkinson's disease patients at the Lagos University Teaching Hospital.
Ojo OO; Oladipo OO; Ojini FI; Sanya EO; Danesi MA; Okubadejo NU
West Afr J Med; 2011; 30(5):319-24. PubMed ID: 22752818
[TBL] [Abstract][Full Text] [Related]
9. Mutations in methylenetetrahydrofolate reductase or cystathionine beta-synthase gene, or a high-methionine diet, increase homocysteine thiolactone levels in humans and mice.
Chwatko G; Boers GH; Strauss KA; Shih DM; Jakubowski H
FASEB J; 2007 Jun; 21(8):1707-13. PubMed ID: 17327360
[TBL] [Abstract][Full Text] [Related]
10. Hyperhomocysteinemia in levodopa-treated patients with Parkinson's disease dementia.
Zoccolella S; dell'Aquila C; Abruzzese G; Antonini A; Bonuccelli U; Canesi M; Cristina S; Marchese R; Pacchetti C; Zagaglia R; Logroscino G; Defazio G; Lamberti P; Livrea P
Mov Disord; 2009 May; 24(7):1028-33. PubMed ID: 19353704
[TBL] [Abstract][Full Text] [Related]
11. Plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with cognitive dysfunctions.
Zoccolella S; Lamberti P; Iliceto G; Diroma C; Armenise E; Defazio G; Lamberti SV; Fraddosio A; de Mari M; Livrea P
Clin Chem Lab Med; 2005; 43(10):1107-10. PubMed ID: 16197306
[TBL] [Abstract][Full Text] [Related]
12. Association of COMT, MTHFR, and SLC19A1(RFC-1) polymorphisms with homocysteine blood levels and cognitive impairment in Parkinson's disease.
Białecka M; Kurzawski M; Roszmann A; Robowski P; Sitek EJ; Honczarenko K; Gorzkowska A; Budrewicz S; Mak M; Jarosz M; Gołąb-Janowska M; Koziorowska-Gawron E; Droździk M; Sławek J
Pharmacogenet Genomics; 2012 Oct; 22(10):716-24. PubMed ID: 22890010
[TBL] [Abstract][Full Text] [Related]
13. Plasma homocysteine levels in Parkinson's disease: role of antiparkinsonian medications.
Zoccolella S; Lamberti P; Armenise E; de Mari M; Lamberti SV; Mastronardi R; Fraddosio A; Iliceto G; Livrea P
Parkinsonism Relat Disord; 2005 Mar; 11(2):131-3. PubMed ID: 15734674
[TBL] [Abstract][Full Text] [Related]
14. The effect of levodopa benserazide hydrochloride on homocysteinemia levels in patients with Parkinson's disease and treatment of hyperhomocysteinemia.
Guo G; Xu S; Cao LD; Wu QY
Eur Rev Med Pharmacol Sci; 2016 Jun; 20(11):2409-12. PubMed ID: 27338068
[TBL] [Abstract][Full Text] [Related]
15. Elevated homocysteine levels in Parkinson's Disease: is there anything besides L-dopa treatment?
Zoccolella S; dell'Aquila C; Specchio LM; Logroscino G; Lamberti P
Curr Med Chem; 2010; 17(3):213-21. PubMed ID: 20214564
[TBL] [Abstract][Full Text] [Related]
16. Serum homocysteine and physical exercise in patients with Parkinson's disease.
Nascimento CM; Stella F; Garlipp CR; Santos RF; Gobbi S; Gobbi LT
Psychogeriatrics; 2011 Jun; 11(2):105-12. PubMed ID: 21707858
[TBL] [Abstract][Full Text] [Related]
17. Hypertrophy of IMC of carotid artery in Parkinson's disease is associated with L-DOPA, homocysteine, and MTHFR genotype.
Nakaso K; Yasui K; Kowa H; Kusumi M; Ueda K; Yoshimoto Y; Takeshima T; Sasaki K; Nakashima K
J Neurol Sci; 2003 Mar; 207(1-2):19-23. PubMed ID: 12614926
[TBL] [Abstract][Full Text] [Related]
18. Hyperhomocysteinemia and methylenetetrahydrofolate reductase polymorphism in patients with Parkinson's disease.
Religa D; Czyzewski K; Styczynska M; Peplonska B; Lokk J; Chodakowska-Zebrowska M; Stepien K; Winblad B; Barcikowska M
Neurosci Lett; 2006 Aug; 404(1-2):56-60. PubMed ID: 16787708
[TBL] [Abstract][Full Text] [Related]
19. Elevated plasma homocysteine levels in L-dopa-treated Parkinson's disease patients with dyskinesias.
Zoccolella S; Lamberti P; Iliceto G; Dell'Aquila C; Diroma C; Fraddosio A; Lamberti SV; Armenise E; Defazio G; de Mari M; Livrea P
Clin Chem Lab Med; 2006; 44(7):863-6. PubMed ID: 16776634
[TBL] [Abstract][Full Text] [Related]
20. Effect of nephrotic syndrome on homocysteine metabolism.
Aminzadeh MA; Gollapudi P; Vaziri ND
Nephrol Dial Transplant; 2011 Apr; 26(4):1244-7. PubMed ID: 20826746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
